The Amyloid-β Pathway in Alzheimer’s Disease
Aug 30, 2021 · Breakthroughs in molecular medicine have positioned the amyloid-β (Aβ) pathway at the center of Alzheimer’s disease (AD) pathophysiology.
The Amyloid-β Pathway in Alzheimer's Disease - PubMed
Here, we systematically review and update the vast state-of-the-art literature of Aβ science with evidence from basic research studies to human genetic and multi-modal biomarker investigations, which supports a crucial role of Aβ pathway dyshomeostasis in AD pathophysiological dynamics.
Amyloid β-based therapy for Alzheimer’s disease: challenges
Jun 30, 2023 · Aducanumab, a monoclonal antibody against Aβ aggregates, has obtained the FDA’s approval as an Alzheimer’s drug for its ability to reduce the level of Aβ plaques in patients with early AD or ...
Proteomic changes in Alzheimer’s disease associated with progressive Aβ ...
Aug 26, 2024 · Using human cerebrospinal fluid proteomics, the authors found that proteins associated with Aβ pathology in Alzheimer disease were mainly expressed in glial cells, whereas those associated...
Trajectory of brain-derived amyloid beta in Alzheimer’s disease: …
Aug 19, 2024 · Alzheimer’s disease (AD) is a progressive neurological disorder that primarily impacts cognitive function. Currently there are no disease-modifying treatments to stop or slow its progression.
Comprehensive Review on Alzheimer’s Disease: Causes and …
Alzheimer’s disease (AD) (named after the German psychiatric Alois Alzheimer) is the most common type of dementia and can be defined as a slowly progressive neurodegenerative disease characterized by neuritic plaques and neurofibrillary tangles as a result of amyloid-beta peptide’s (Aβ) accumulation in the most affected area of the brain ...
The physiological roles of tau and Aβ: implications for Alzheimer’s ...
Tau and amyloid beta (Aβ) are the prime suspects for driving pathology in Alzheimer’s disease (AD) and, as such, have become the focus of therapeutic development. Recent research, however, shows that these proteins have been highly conserved ...
Amyloid β-based therapy for Alzheimer's disease: challenges
Jun 30, 2023 · Amyloid β protein (Aβ) is the main component of neuritic plaques in Alzheimer's disease (AD), and its accumulation has been considered as the molecular driver of Alzheimer's pathogenesis and progression. Aβ has been the prime target for the development of AD therapy.
Alzheimer Disease Pathogenesis: Insights From Molecular and …
Keywords: Alzheimer disease, amyloid plaques, neurofibrillary tangles, PET, Down syndrome, Aβ, tau, oligomer. Alzheimer’s Disease: Genetics and Neuropathology Genetics of AD. AD is the most common cause of dementia, accounting for up to 70% of cases (Plassman et al., 2007).
Peripheral clearance of brain-derived Aβ in Alzheimer's disease ...
May 7, 2020 · Alzheimer’s disease (AD) is the most common form of dementia, and disease-modifying therapies are not available to date. The extracellular senile plaques formed by the deposition of amyloid-beta (Aβ) peptide are the specific hallmark of AD.